Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1973 Sep;4(3):302–305. doi: 10.1128/aac.4.3.302

Amphotericin B Therapy in an Anephric Patient

Harvey A Feldman a,1, John D Hamilton a, Robert A Gutman a
PMCID: PMC444546  PMID: 4586143

Abstract

Serum levels of amphotericin B were serially determined during and after a course of therapy in an anephric patient who developed systemic candidiasis after an unsuccessful renal transplantation. There was no progressive accumulation of drug in serum, and the pattern of disappearance of drug from serum was similar to that published for patients with normal renal function. The dialyzability of amphotericin B was studied in vivo during a 6-h period of hemodialysis, by an in vitro dialysis of amphotericin B in water by using similar equipment, and a Pellicon membrane filter which retains molecular species of 100,000 molecular weight and higher. These studies revealed that the drug is not dialyzable with conventional hemodialysis membranes, regardless of protein binding in plasma, and is excluded from passing through the Pellicon membrane filter.

Full text

PDF
302

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barousse A. P., De Bercovich C., Firmat J., Malamud E. E. Extraccion de amphotericin-B por hemodiálysis extracorpórea. Medicina (B Aires) 1971 Jan-Feb;31(1):26–30. [PubMed] [Google Scholar]
  2. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
  4. Hart P. D., Russell E., Jr, Remington J. S. The compromised host and infection. II. Deep fungal infection. J Infect Dis. 1969 Aug;120(2):169–191. doi: 10.1093/infdis/120.2.169. [DOI] [PubMed] [Google Scholar]
  5. Klainer A. S., Beisel W. R. Opportunistic infection: a review. Am J Med Sci. 1969 Dec;258(6):431–456. doi: 10.1097/00000441-196912000-00007. [DOI] [PubMed] [Google Scholar]
  6. LOURIA D. B. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiotic Med Clin Ther (New York) 1958 May;5(5):295–301. [PubMed] [Google Scholar]
  7. Montgomerie J. Z., Kalmanson G. M., Guze L. B. Renal failure and infection. Medicine (Baltimore) 1968 Jan;47(1):1–32. doi: 10.1097/00005792-196801000-00001. [DOI] [PubMed] [Google Scholar]
  8. Richardson J. A., Derrow A. M., Borchardt K. A. Therapy with amphotericin B of Candida septicemia in the presence of acute renal failure. Invest Urol. 1968 Nov;6(3):247–250. [PubMed] [Google Scholar]
  9. Rifkind D., Marchioro T. L., Schneck S. A., Hill R. B., Jr Systemic fungal infections complicating renal transplantation and immunosuppressive therapy. Clinical, microbiologic, neurologic and pathologic features. Am J Med. 1967 Jul;43(1):28–38. doi: 10.1016/0002-9343(67)90146-5. [DOI] [PubMed] [Google Scholar]
  10. Shadomy S., McCay J. A., Schwartz S. I. Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol. 1969 Apr;17(4):497–503. doi: 10.1128/am.17.4.497-503.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. VOGEL R. A., CRUTCHER J. C. Studies on the bioassay and excretion of amphotericin B in patients with systemic mycoses. Antibiotic Med Clin Ther (New York) 1958 Aug;5(8):501–506. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES